Deciphering MOSPD1’s impact on breast cancer progression and therapeutic response
Elevated MOSPD1 levels in BC suggest its potential as a biomarker for adverse outcomes. Targeting MOSPD1, particularly with anti-PD-L1 therapy, may effectively inhibit BC tumor growth and modulate immune responses. This study emphasizes the significance of MOSPD1 in BC pathophysiology and highlights its promise as a therapeutic target.
Authors
- Yiling Jiang (ORCID: https://orcid.org/0000-0002-1236-7550)
- Lijun Zeng (ORCID: https://orcid.org/0000-0002-6690-1114)
- Yuehua Li (ORCID: https://orcid.org/0000-0003-2037-1071)
- Xiaojun Liu (ORCID: https://orcid.org/0000-0002-5972-907X)
- Wei Du (ORCID: https://orcid.org/0000-0002-3628-3298)
- Sixuan Wu (ORCID: https://orcid.org/0000-0001-7690-723X)
- Baohong Jiang (ORCID: https://orcid.org/0000-0002-8573-1536)
- Lunqi Luo (ORCID: https://orcid.org/0009-0009-0115-470X)
- Yuanbin Tang (ORCID: https://orcid.org/0009-0007-0124-6319)
- Lianjie Ouyang (ORCID: https://orcid.org/0009-0004-9450-2024)
Institutions
- Central South University (CN)
- The First People's Hospital of Changde (CN)
- First Affiliated Hospital of University of South China (CN)
- University of South China (CN)
Publication Details
- Journal
- Biology Direct
- Published
- 2024-10-05
- DOI
- https://doi.org/10.1186/s13062-024-00531-9
- Citations
- 2
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Natural Science Foundation of Hunan Province